CANADIANS DESERVE ACCESS TO INNOVATIVE OVARIAN CANCER TREATMENTS NOW
Eligible Canadians are still waiting to access the first meaningful new ovarian cancer treatment in over a decade.
National negotiations to bring ELAHERE (mirvetuximab soravtansine) to eligible Canadians stalled earlier this year. We are urging our nation’s decision-makers to restart these negotiations.
Your voice has the power to make that happen
Click the button that applies to you to send our email template to your representative
You will be able to customize your message to share your personal story.
Personalized medicine is the future of healthcare. Making ELAHERE accessible to Canadians now could mean more personalized treatments for many healthcare needs in the future.
What is ELAHERE?
For women living with this form of ovarian cancer, treatment options are limited because chemotherapy is no longer effective. It is the first significant new treatment option for women living with this type of ovarian cancer in more than a decade.
Why is access to ELAHERE so important for Canadian women?
Canadians living with platinum-resistant ovarian cancer do not have the luxury of time. For those living with this form of the disease, treatment options are limited. While ELAHERE is accessible in other countries, it is not yet available to Canadians through public healthcare. Losing momentum means losing ground for women who cannot and should not have to wait for access to this treatment.
What has happened so far to make ELAHERE accessible to Canadians?
Since then, they have worked with Health Canada, ELAHERE manufacturer AbbVie, and federal, provincial and territorial partners to push for regulatory review, approval, and public reimbursement.
- March 2025 – OCC patient submission to Canada’s Drug Agency and Institut national d’excellence en santé et services sociaux (INESSS).
- September 2025 – Health Canada approves ELAHERE for use in Canada.
- October 2025 – Canada’s Drug Agency recommends that ELAHERE be reimbursed by public drug plans for the treatment of eligible adults.
- December 2025 – Letter of intent sent by the pan-Canadian Pharmaceutical Alliance (pCPA) to the drug’s manufacturer, AbbVie letting them know that they are ready to start negotiating.
- May 2026 – negotiations between the pCPA and AbbVie end without an agreement, stalling the process to make ELAHERE available to Canadians.